- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01996254
Electrical Stimulation for the Treatment of Post-Amputation Pain Using the SPRINT System
March 25, 2020 updated by: SPR Therapeutics, Inc.
A Randomized, Double-Blinded, Placebo-Controlled, Multicenter Pilot Study of the SPRINT Peripheral Nerve Stimulation (PNS) System for the Treatment of Post-Amputation Pain
The purpose of this study is to determine if electrical stimulation (small levels of electricity) can safely and effectively reduce post-amputation pain.
This study involves a device called the SPRINT System.
The SPRINT System delivers mild electrical stimulation to nerves in the residual limb.
The SPRINT System includes a small wire (called a "lead") that is placed through the skin in the upper leg.
It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- Arizona Pain
-
-
California
-
La Jolla, California, United States, 92093
- University of California San Diego
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Denver Clinic for Extremities at Risk
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- International Spine, Pain and Performance Center
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33334
- Holy Cross Hospital
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Maryland
-
Bethesda, Maryland, United States, 20889
- Walter Reed National Military Medical Center
-
-
New Jersey
-
Shrewsbury, New Jersey, United States, 07702
- Premier Pain Centers
-
-
New York
-
New York, New York, United States, 10022
- Ainsworth Institute Of Pain Management
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- Center for Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- At least 18 years old
- Traumatic lower extremity amputation(s)
- Healed amputation and healthy residual limb based upon the investigator's evaluation
Key Exclusion Criteria:
- Change of prescribed medications affecting pain within the past 4 weeks
- Compromised immune system based on medical history
- Implanted electronic device
- Bleeding disorder
- History of valvular heart disease
- Confounding central nervous system injuries and disorders
- History of recurrent skin infections
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SPRINT Group 1
Subjects in Group 1 will have a Lead placed in the residual limb in the upper leg.
These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
|
The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb.
The SPRINT System includes a small wire (called a "Lead") that is placed through the skin in the upper leg.
It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Other Names:
|
SHAM_COMPARATOR: SPRINT Group 2
Subjects in Group 2 will have a Lead placed in the residual limb in the upper leg.
These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System for a total of 8 weeks.
They will receive 4 weeks of stimulation and 4 weeks with no stimulation.
|
The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb.
The SPRINT System includes a small wire (called a "Lead") that is placed through the skin in the upper leg.
It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Group 1 (Treatment) and Group 2 (Control) Subjects That Achieved ≥ 50% Reduction in All Qualifying Areas of Pain in the First 4 Weeks of Treatment
Time Frame: Baseline and Weeks 1-4 Post-Start of Treatment
|
Subjects completed daily diaries to record their average daily pain intensity scores for each qualifying region of pain (phantom limb pain and/or residual limb pain).
These pain intensity questions were excerpted from the Brief Pain Inventory - Short Form Question 5 (BPI-5).
The BPI-5 is an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine."
Post-amputation pain intensity scores were determined for each subject by taking the mean of the daily average pain intensity scores from their diaries at Baseline compared to the mean score for the same region(s) of pain reported over 4 weeks after the Start of Treatment (i.e., the average of all diary scores during this period).
Subjects that achieved ≥ 50% reduction in their qualifying area(s) of pain were considered successful.
Missing diary data were replaced using 1-week BPI-5 recall; if recall scores were unavailable, baseline values were imputed.
|
Baseline and Weeks 1-4 Post-Start of Treatment
|
Number of Subjects That Experienced at Least One Study-Related Adverse Event in Treatment and Control Groups
Time Frame: Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
At each study visit following the baseline assessment at Visit 1, subjects were questioned if any changes in their medical status or condition had occurred since their previous visit.
If the subject experienced a change that was an adverse event, an Adverse Event Form was completed by the site.
The number of subjects that experienced at least one study-related adverse event is reported here.
|
Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Group 1 (Treatment) Subjects That Experienced ≥ 50% Reduction in All Qualifying Areas of Pain During Weeks 5-8 Compared to Group 2 (Control) Subjects During Weeks 1-4
Time Frame: Baseline and Weeks 1-8 Post-Start of Treatment
|
Subjects completed daily diaries to record their average daily pain intensity scores for each qualifying region of pain (phantom limb pain and/or residual limb pain).
These pain intensity questions were excerpted from the Brief Pain Inventory - Short Form Question 5 (BPI-5) on a scale from 0 to 10, where 0 indicates no pain and 10 indicates pain as bad as you can imagine.
Post-amputation pain intensity scores were determined by taking the mean of the daily average pain intensity scores at baseline and over weeks 5-8 post-start of treatment for Group 1 subjects and over weeks 1-4 post-start of treatment for Group 2 subjects.
Subjects that achieved ≥ 50% reduction in their qualifying area(s) of pain were considered successful.
Missing diary data were replaced using the bi-weekly BPI-5 recall scores; if unavailable, the BPI-5 recall from the follow-up visit was used.
The number of successes in each group is reported.
|
Baseline and Weeks 1-8 Post-Start of Treatment
|
Proportion of Subjects That Experienced ≥ 50% Reduction in All Qualifying Areas of Pain at Months 3-12 Post-Start of Treatment
Time Frame: 3-months Post-SOT, 4-months Post-SOT, 5-months Post-SOT, 6-months Post-SOT, 7-months Post-SOT, 8-months Post-SOT, 9-months Post-SOT, 10-months Post-SOT, 11-months Post-SOT, and 12-months Post-SOT
|
Subjects were asked to recall and rate their average pain intensity over the past week (BPI-SF question 5) for each qualifying area of pain (phantom and/or residual limb pain) on a scale from 0 to 10, where 0 indicates no pain and 10 indicates pain as bad as you can imagine.
The average pain intensity score(s) at baseline were compared to the same region(s) of pain at monthly intervals from months 3-12 post-start of treatment (SOT).
Subjects that achieved ≥ 50% reduction in their qualifying area(s) of pain were considered successful.
Certain time points for Group 2 (i.e., after crossover) were considered exploratory, but are reported with this outcome measure for ease of data entry and readability.
|
3-months Post-SOT, 4-months Post-SOT, 5-months Post-SOT, 6-months Post-SOT, 7-months Post-SOT, 8-months Post-SOT, 9-months Post-SOT, 10-months Post-SOT, 11-months Post-SOT, and 12-months Post-SOT
|
Proportion of Subjects That Experienced ≥50% Reduction in Average Pain Interference With Daily Activities
Time Frame: Baseline, 4-weeks Post-Start of Treatment (SOT), 8-weeks Post-SOT, 3-months Post-SOT, 4-months Post-SOT, 5-months Post-SOT, 6-months Post-SOT, 7-months Post-SOT, 8-months Post-SOT, 9-months Post-SOT, 10-months Post-SOT, 11-mo Post-SOT, & 12-mo Post-SOT
|
Degree of post-amputation pain that interfered with 7 aspects of daily life was rated [scale (0 to 10) with higher scores indicating greater interference].
The 7 individual scores were averaged to provide an overall pain interference score.
Pain interference questions (Brief Pain Inventory - Short Form Question 9) were used for each qualifying area of pain (phantom and/or residual limb pain).
Group 1 subjects: baseline average pain interference scores were compared to average pain interference scores for the same region(s) of pain at each monthly interval after the start of therapy.
Group 2 subjects: baseline average pain interference scores were compared to their average score at the end of 4 weeks.
Proportion of successes (subjects that experienced ≥50% reduction in average pain interference scores) is reported.
Certain time points for Group 2 (i.e., after crossover) were considered exploratory but are being reported here for ease of data entry and readability.
|
Baseline, 4-weeks Post-Start of Treatment (SOT), 8-weeks Post-SOT, 3-months Post-SOT, 4-months Post-SOT, 5-months Post-SOT, 6-months Post-SOT, 7-months Post-SOT, 8-months Post-SOT, 9-months Post-SOT, 10-months Post-SOT, 11-mo Post-SOT, & 12-mo Post-SOT
|
Proportion of Group 1 (Treatment) Subjects That Experienced ≥ 10-point Reduction in Pain Disability at Monthly Intervals Post-Start of Treatment Compared to Group 2 (Control) Subjects at Week 4 Post-Start of Treatment
Time Frame: Baseline, 4-weeks Post-Start of Treatment (SOT), 8-weeks Post-SOT, 3-months Post-SOT, 4-months Post-SOT, 5-months Post-SOT, 6-months Post-SOT, 7-months Post-SOT, 8-months Post-SOT, 9-months Post-SOT, 10-months Post-SOT, 11-mo Post-SOT, & 12-mo Post-SOT
|
The Pain Disability Index (PDI) is a validated survey measuring the degree pain disrupts 7 categories of life activities on a scale from 0 to 10, with higher scores indicating greater disability.
The 7 scores were summed for each subject to provide an overall pain disability score.
For Group 1 subjects, the baseline average PDI score was compared to PDI scores at monthly intervals.
For Group 2 subjects, the baseline average PDI score was compared to their PDI score at the end of 4 weeks.
The proportion of successes (subjects reporting ≥10 point reduction in PDI scores from baseline) are reported for Group 1 subjects.
Certain time points for Group 2 (i.e., after crossover) were considered exploratory but are being reported within this outcome measure for ease of data entry and readability.
|
Baseline, 4-weeks Post-Start of Treatment (SOT), 8-weeks Post-SOT, 3-months Post-SOT, 4-months Post-SOT, 5-months Post-SOT, 6-months Post-SOT, 7-months Post-SOT, 8-months Post-SOT, 9-months Post-SOT, 10-months Post-SOT, 11-mo Post-SOT, & 12-mo Post-SOT
|
Depression at Monthly Intervals After Start of Therapy
Time Frame: Baseline, 4-weeks Post-Start of Treatment (SOT), 8-weeks Post-SOT, 3-months Post-SOT, 4-months Post-SOT, 5-months Post-SOT, 6-months Post-SOT, 7-months Post-SOT, 8-months Post-SOT, 9-months Post-SOT, 10-months Post-SOT, 11-mo Post-SOT, & 12-mo Post-SOT
|
The Beck Depression Inventory (BDI-II) is a validated, 21-question survey used to measure depression severity.
Question are rated on a scale from 0 to 3, and the scores from each question are totaled to provide an overall score ranging between 0 to 63. Scores from 0-13 indicate minimal depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression.
Group 1 subjects: baseline BDI-II score was compared to BDI-II scores at monthly intervals.
Group 2 subjects: baseline BDI-II score was compared to their BDI-II score at the end of 4 weeks.
The percent change from baseline to each monthly interval is reported.
Certain timepoints for Group 2 (i.e., after crossover) were considered exploratory but are being reported within this outcome measure for ease of data entry and readability.
|
Baseline, 4-weeks Post-Start of Treatment (SOT), 8-weeks Post-SOT, 3-months Post-SOT, 4-months Post-SOT, 5-months Post-SOT, 6-months Post-SOT, 7-months Post-SOT, 8-months Post-SOT, 9-months Post-SOT, 10-months Post-SOT, 11-mo Post-SOT, & 12-mo Post-SOT
|
Change in Opioid Analgesic Usage From Baseline
Time Frame: Baseline, 4-weeks Post-Start of Treatment (SOT), and 8-weeks Post-SOT
|
Changes in opioid analgesic usage were calculated using morphine equivalent dosing (MED) for subjects who were using opioid analgesics at baseline.
Subjects completed daily diaries in which they tracked their use of analgesic medications.
For Group 1 subjects, the mean daily MED from the baseline diary was compared to the mean daily MED during week 4 and week 8.
For Group 2 subjects, the daily MED from the baseline diary was compared to the daily MED during week 4 only.
The median percent change from baseline is reported.
Certain time points for Group 2 (i.e., after crossover) were considered exploratory but are being reported within this outcome measure for ease of data entry and readability.
|
Baseline, 4-weeks Post-Start of Treatment (SOT), and 8-weeks Post-SOT
|
Percent Change in Hours of Daily Prosthetic Usage
Time Frame: Baseline, 4-weeks Post-Start of Treatment (SOT), and 8-weeks Post-SOT
|
Subjects completed daily diaries in which they tracked the number of hours of their prosthetic usage.
The 7-day mean prosthetic use was calculated for each subject from their baseline diary and compared to the 7-day mean from week 4 and week 8.
The percent change from baseline was then calculated for each subject at each time point (i.e., 4-week median vs. baseline median and 8-week median vs. baseline median).
A positive value indicates an increase in prosthetic usage.
|
Baseline, 4-weeks Post-Start of Treatment (SOT), and 8-weeks Post-SOT
|
Subject Satisfaction Survey
Time Frame: Visit 11 (8-weeks post-Start of Treatment (SOT))
|
Subjects completed a sponsor-developed survey with questions pertaining to their feelings about therapy as delivered by the SPRINT Beta Stimulation System as a method for managing chronic post-amputation pain.
Subjects were asked to report on their experience using the therapy.
Depending on the question, subjects were asked to indicate their agreement with the question (strongly disagree, agree, neutral, disagree, strongly disagree), their comfort with the therapy (very uncomfortable, a little bit uncomfortable, fairly comfortable, very comfortable), or when pain relief was felt (immediately, a few minutes later, a few hours later, more than a day later or never).
Responses are presented for key groups of questions related to the therapy whereby answer options are considered affirmative for strongly agree/agree, very easy/easy, very comfortable/comfortable.
|
Visit 11 (8-weeks post-Start of Treatment (SOT))
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Josh Boggs, PhD, SPR Therapeutics
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gilmore CA, Ilfeld BM, Rosenow JM, Li S, Desai MJ, Hunter CW, Rauck RL, Nader A, Mak J, Cohen SP, Crosby ND, Boggs JW. Percutaneous 60-day peripheral nerve stimulation implant provides sustained relief of chronic pain following amputation: 12-month follow-up of a randomized, double-blind, placebo-controlled trial. Reg Anesth Pain Med. 2019 Nov 17:rapm-2019-100937. doi: 10.1136/rapm-2019-100937. Online ahead of print.
- Gilmore C, Ilfeld B, Rosenow J, Li S, Desai M, Hunter C, Rauck R, Kapural L, Nader A, Mak J, Cohen S, Crosby N, Boggs J. Percutaneous peripheral nerve stimulation for the treatment of chronic neuropathic postamputation pain: a multicenter, randomized, placebo-controlled trial. Reg Anesth Pain Med. 2019 Jun;44(6):637-645. doi: 10.1136/rapm-2018-100109. Epub 2019 Apr 5.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (ACTUAL)
January 28, 2019
Study Completion (ACTUAL)
January 28, 2019
Study Registration Dates
First Submitted
November 18, 2013
First Submitted That Met QC Criteria
November 21, 2013
First Posted (ESTIMATE)
November 27, 2013
Study Record Updates
Last Update Posted (ACTUAL)
March 26, 2020
Last Update Submitted That Met QC Criteria
March 25, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0123-CSP-000
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phantom Limb Pain
-
Shirley Ryan AbilityLabCoapt, LLCRecruitingLower Limb Amputation Below Knee (Injury) | Lower Limb Amputation Above Knee (Injury) | Amputation | Phantom Limb Pain | Phantom Pain | Phantom Sensation | Lower Limb Amputation Knee | Lower Limb Amputation at Ankle (Injury) | Upper Limb Amputation at the Hand | Upper Limb Amputation at the Wrist | Upper... and other conditionsUnited States
-
Artur BiktimirovEnrolling by invitationAmputation | Phantom Limb Pain | Lower Limb Amputation | Phantom PainRussian Federation
-
United States Naval Medical Center, San DiegoUnknownPhantom Limb Pain | Phantom Pain | Phantom Sensation | PseudomeliaUnited States
-
VA Office of Research and DevelopmentRecruitingChronic Pain | Lower Limb Amputation | Phantom Pain | Upper Limb Amputation | Phantom Limb Pain After AmputationUnited States
-
Artur BiktimirovEnrolling by invitationAmputation | Phantom Limb Pain | Phantom PainRussian Federation
-
Centre d'Investigation Clinique et Technologique...CompletedAmputation | Phantom Pain Following Amputation of Lower LimbFrance
-
University of California, San DiegoCompletedPhantom Limb Pain | Residual Limb PainUnited States
-
University of California, San DiegoVarian Medical Systems; Epimed InternationalRecruitingAmputation, Traumatic | Phantom Limb Pain | Phantom Pain Following Amputation of Lower Limb | Amputation, SurgicalUnited States
-
Cairo UniversityActive, not recruitingPhantom Pain Following Amputation of Lower LimbEgypt
-
University of Alabama at BirminghamCompletedAmputation | Phantom Limb Pain | Residual Limb PainUnited States
Clinical Trials on SPRINT Peripheral Nerve Stimulation (PNS) System
-
SPR Therapeutics, Inc.CompletedPain | Postoperative Pain | Orthopedic Disorder | Total Knee Arthroplasty | Total Knee ReplacementUnited States
-
SPR Therapeutics, Inc.TerminatedAmputation | Neuropathic PainUnited States
-
SPR Therapeutics, Inc.United States Department of DefenseActive, not recruitingPostoperative Pain | Total Knee Arthroplasty | Total Knee Replacement | Partial Knee ReplacementUnited States
-
SPR Therapeutics, Inc.RecruitingCervicogenic Headache | Occipital NeuralgiaUnited States
-
SPR Therapeutics, Inc.CompletedBack Pain | Low Back PainUnited States
-
SPR Therapeutics, Inc.CompletedPain | Postoperative Pain | Total Knee Arthroplasty | Total Knee Replacement | Orthopedic DisordersUnited States
-
Stanford UniversitySPR Therapeutics, Inc.WithdrawnPostoperative Pain | Knee Injuries | Surgery | Total Knee Arthroplasty | Knee Pain Chronic | Chronic Postoperative Pain | Injury; Nerve, Peripheral, Multiple | Chronic Post-Procedural PainUnited States
-
SPR Therapeutics, Inc.United States Department of DefenseActive, not recruitingBack Pain | Low Back PainUnited States
-
University of Sao Paulo General HospitalNational Institute of Neurological Disorders and Stroke (NINDS); The Cleveland... and other collaboratorsCompleted
-
Mansoor Aman, MDRecruitingOsteoarthritis | Osteoarthritis, KneeUnited States